<!DOCTYPE html>
<html>
<head>
    <title>全文阅读--XML全文阅读--中国知网</title>
    <link rel="icon" href="/kxreader/favicon.ico" />
    <link rel="shortcut Icon" href="/kxreader/favicon.ico" />
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
    <meta name="keywords" content="文献 XML KBASE CNKI 中国知网" />
    <meta name="description" content="XML文献检索" />
    <link href="/kxreader/Content/css/detail?v=NOOK-mvTMnxl11s6oPYV0boPXN3iP4N7Rc-A56nk4KI1" rel="stylesheet"/>

    <script type="text/javascript">
        var APPPATH = '/kxreader';
    </script>
</head>

<body>
    
<script type="text/javascript" src="//login.cnki.net/TopLogin/api/loginapi/get?type=top&amp;localCSS=&amp;returnurl=%2f%2fkns.cnki.net%2fKXReader%2fDetail%3fTIMESTAMP%3d637141665341826250%26DBCODE%3dCJFD%26TABLEName%3dCJFDLAST2019%26FileName%3dXXGK201904015%26RESULT%3d1%26SIGN%3dM5aGRzR42ZVtSMh6UIaRh0OM%252fPs%253d"></script>

<div id="headerBox" class="header">
    <div class="topbar">
        <div class="textalign">
            <a href="/kxreader/Detail?dbcode=CJFD&amp;filename=XXGK201904015&amp;align=md">
                <i class="icon-cen active" title="居中对齐"></i>
            </a>
            <a href="/kxreader/Detail?dbcode=CJFD&amp;filename=XXGK201904015&amp;align=lt">
                <i class="icon-left " title="左对齐"></i>
            </a>
        </div>
        <h6 class="free-tip"><i class="icon"></i>HTML阅读开放试用阶段，欢迎体验！</h6>
    </div>
</div>

    



<div class="btn-link" style="display: none"><a target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=XXGK201904015&amp;v=MTUyMjJDVVI3cWZadVptRnlqblY3M09QVFhNWmJHNEg5ak1xNDlFWVlRS0RIODR2UjRUNmo1NE8zenFxQnRHRnI=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">知网节</a></div>

    <div class="main">

        

    <div class="sidebar-a">
        <!--sidebar start-->
        <div class="sidenav">
            <div class="arrow"><span></span></div>
            <!--sidebar_list start-->
            <dl class="sidenav-list">
                    <dt class="tit">目录结构</dt>
                            <dd class="guide">
                                    <p><a href="#36" data-title="&lt;b&gt;1 资料与方法&lt;/b&gt; "><b>1 资料与方法</b></a><i></i></p>
                                                                    <ul class="contentbox">
                                                <li><a href="#37" data-title="1.1 一般资料">1.1 一般资料</a></li>
                                                <li><a href="#39" data-title="1.2 治疗方法">1.2 治疗方法</a></li>
                                                <li><a href="#41" data-title="1.3 观察指标">1.3 观察指标</a></li>
                                                <li><a href="#43" data-title="1.4 统计学方法">1.4 统计学方法</a></li>
                                    </ul>
                            </dd>
                            <dd class="guide">
                                    <p><a href="#46" data-title="&lt;b&gt;2 结 果&lt;/b&gt; "><b>2 结 果</b></a><i></i></p>
                                                                    <ul class="contentbox">
                                                <li><a href="#47" data-title="2.1 两组治疗前后NIHSS评分相比较">2.1 两组治疗前后NIHSS评分相比较</a></li>
                                                <li><a href="#49" data-title="2.2 两组治疗前、治疗30d后炎症因子水平相比较">2.2 两组治疗前、治疗30d后炎症因子水平相比较</a></li>
                                                <li><a href="#55" data-title="2.3 两组治疗前、治疗30d后MCP-1和VE-cadherin水平相比较">2.3 两组治疗前、治疗30d后MCP-1和VE-cadherin水平相比较</a></li>
                                                <li><a href="#57" data-title="2.4 两组治疗前、治疗30d后颈动脉粥样硬化指标相比较">2.4 两组治疗前、治疗30d后颈动脉粥样硬化指标相比较</a></li>
                                                <li><a href="#63" data-title="2.5 两组治疗过程中不良反应发生率相比较">2.5 两组治疗过程中不良反应发生率相比较</a></li>
                                    </ul>
                            </dd>
                            <dd class="guide">
                                    <p><a href="#65" data-title="&lt;b&gt;3 讨 论&lt;/b&gt; "><b>3 讨 论</b></a><i></i></p>
                                                            </dd>
                            <dd class="guide">
                                    <p><a href="#" data-title="文内图表 ">文内图表</a><i></i></p>
                                                                    <ul class="contentbox">
                                                <li><a href="#51" data-title="&lt;b&gt;表&lt;/b&gt;1 &lt;b&gt;两组治疗前后&lt;/b&gt;NIHSS&lt;b&gt;评分相比较&lt;/b&gt; (&lt;image id=&quot;86&quot; type=&quot;formula&quot; href=&quot;images/XXGK201904015_08600.jpg&quot; display=&quot;inline&quot; placement=&quot;inline&quot;&gt;&lt;alt&gt;&lt;/alt&gt;&lt;/image&gt;&#177;s) "><b>表</b>1 <b>两组治疗前后</b>NIHSS<b>评分相比较</b> (<image id="86" type="formula" href="images/XXGK201904015_08600.jpg" display="inline" placement="inline"><alt></alt></image>±s) </a></li>
                                                <li><a href="#53" data-title="&lt;b&gt;表&lt;/b&gt;2 &lt;b&gt;两组治疗前、治疗&lt;/b&gt;30d&lt;b&gt;后炎症因子水平相比较&lt;/b&gt; (&lt;image id=&quot;87&quot; type=&quot;formula&quot; href=&quot;images/XXGK201904015_08700.jpg&quot; display=&quot;inline&quot; placement=&quot;inline&quot;&gt;&lt;alt&gt;&lt;/alt&gt;&lt;/image&gt;&#177;s) "><b>表</b>2 <b>两组治疗前、治疗</b>30d<b>后炎症因子水平相比较</b> (<image id="87" type="formula" href="images/XXGK201904015_08700.jpg" display="inline" placement="inline"><alt></alt></image>±s) </a></li>
                                                <li><a href="#59" data-title="&lt;b&gt;表&lt;/b&gt;3 &lt;b&gt;两组治疗前、治疗&lt;/b&gt;30d&lt;b&gt;后&lt;/b&gt;MCP-1&lt;b&gt;和&lt;/b&gt;VE-cadherin&lt;b&gt;水平相比较&lt;/b&gt; (&lt;image id=&quot;88&quot; type=&quot;formula&quot; href=&quot;images/XXGK201904015_08800.jpg&quot; display=&quot;inline&quot; placement=&quot;inline&quot;&gt;&lt;alt&gt;&lt;/alt&gt;&lt;/image&gt;&#177;s) "><b>表</b>3 <b>两组治疗前、治疗</b>30d<b>后</b>MCP-1<b>和</b>VE-cadherin<b>水平相比较</b> (<image id="88" type="formula" href="images/XXGK201904015_08800.jpg" display="inline" placement="inline"><alt></alt></image>±s) </a></li>
                                                <li><a href="#61" data-title="&lt;b&gt;表&lt;/b&gt;4 &lt;b&gt;两组治疗前、治疗&lt;/b&gt;30d&lt;b&gt;后颈动脉粥样硬化指标相比较&lt;/b&gt; (&lt;image id=&quot;89&quot; type=&quot;formula&quot; href=&quot;images/XXGK201904015_08900.jpg&quot; display=&quot;inline&quot; placement=&quot;inline&quot;&gt;&lt;alt&gt;&lt;/alt&gt;&lt;/image&gt;&#177;s) "><b>表</b>4 <b>两组治疗前、治疗</b>30d<b>后颈动脉粥样硬化指标相比较</b> (<image id="89" type="formula" href="images/XXGK201904015_08900.jpg" display="inline" placement="inline"><alt></alt></image>±s) </a></li>
                                    </ul>
                            </dd>
                                    <dd class="guide">
                                        <h6>
                                            <p><a href="#a_bibliography">参考文献</a> </p>
                                        </h6>
                                    </dd>

            </dl>
        </div>
        <!--sidebar end-->
        &nbsp;
        <!--此处有一空格符 勿删-->
    </div>

                <div class="sidebar-b three-collumn" style="width:0;">
            <div class="refer" style="width: 0;">
                <div class="arrow off" title="参考文献"><span></span></div>
                <div class="js-scrollbox" >
                    
                    <div class="subbox active">
                        <h4>
                            <span class="tit">参考文献</span>
                            <a class="close" href="javascript:void(0)">x</a>
                        </h4>
                        <div class="side-scroller">
                            <ul class="refer-list">
                                <li id="5">


                                    <a id="bibliography_1" title="申丽红, 梁小乐, 高旭光.急性脑梗死患者微栓子与颈动脉粥样硬化斑块的相关性研究[J].中华老年心脑血管病杂志, 2014, 16 (3) :237-239." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=LNXG201403005&amp;v=MjI2ODBLU1BUYWJHNEg5WE1ySTlGWVlRS0RIODR2UjRUNmo1NE8zenFxQnRHRnJDVVI3cWZadVptRnlqblY3M08=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[1]</b>
                                        申丽红, 梁小乐, 高旭光.急性脑梗死患者微栓子与颈动脉粥样硬化斑块的相关性研究[J].中华老年心脑血管病杂志, 2014, 16 (3) :237-239.
                                    </a>
                                </li>
                                <li id="7">


                                    <a id="bibliography_2" title="张全新.大剂量阿托伐他汀治疗急性脑梗死患者的疗效观察[J].中华老年心血管病杂志, 2014, 16 (8) :843-845." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=LNXG201408020&amp;v=MzIyNDBESDg0dlI0VDZqNTRPM3pxcUJ0R0ZyQ1VSN3FmWnVabUZ5am5WNzNPS1NQVGFiRzRIOVhNcDQ5SFpJUUs=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[2]</b>
                                        张全新.大剂量阿托伐他汀治疗急性脑梗死患者的疗效观察[J].中华老年心血管病杂志, 2014, 16 (8) :843-845.
                                    </a>
                                </li>
                                <li id="9">


                                    <a id="bibliography_3" title="李娟.氯吡格雷联合拜阿司匹林在急性脑梗死患者抗血小板聚集中的应用[J].医学综述, 2015, 21 (19) :3616-3618." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=YXZS201519065&amp;v=MjMzOTN5am5WNzNPUERYUmZiRzRIOVROcG85RFlZUUtESDg0dlI0VDZqNTRPM3pxcUJ0R0ZyQ1VSN3FmWnVabUY=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[3]</b>
                                        李娟.氯吡格雷联合拜阿司匹林在急性脑梗死患者抗血小板聚集中的应用[J].医学综述, 2015, 21 (19) :3616-3618.
                                    </a>
                                </li>
                                <li id="11">


                                    <a id="bibliography_4" title="杜文秀, 李艳艳, 史路遥, 等.阿托伐他汀钙对急性脑梗死患者血浆S100β和高迁移率族蛋白1水平的影响[J].中华老年心脑血管病杂志, 2016, 18 (9) :938-942." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=LNXG201609012&amp;v=MjAzNzE0TzN6cXFCdEdGckNVUjdxZlp1Wm1GeWpuVjczT0tTUFRhYkc0SDlmTXBvOUVab1FLREg4NHZSNFQ2ajU=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[4]</b>
                                        杜文秀, 李艳艳, 史路遥, 等.阿托伐他汀钙对急性脑梗死患者血浆S100β和高迁移率族蛋白1水平的影响[J].中华老年心脑血管病杂志, 2016, 18 (9) :938-942.
                                    </a>
                                </li>
                                <li id="13">


                                    <a id="bibliography_5" title="中华医学会全国第四届脑血管病学术会议组.各类脑血管疾病诊断要点[J].中华神经科杂志, 1996, 29 (6) :379." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=ZHSJ606.025&amp;v=MTE5Mjl1ZHVGU3puVlE9PVB5WFlaTFc0R00vTXJZb3FZZXNNRFE0eHp4WVM3MHgrUUh2cjMzMDNlYkNVUmJ1ZmI=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[5]</b>
                                        中华医学会全国第四届脑血管病学术会议组.各类脑血管疾病诊断要点[J].中华神经科杂志, 1996, 29 (6) :379.
                                    </a>
                                </li>
                                <li id="15">


                                    <a id="bibliography_6" title="中华医学会神经病学分会脑血管病学组急性缺血性脑卒中诊治指南撰写组.中国急性缺血性脑卒中诊治指南2010[J].中华神经科杂志, 2010, 43 (2) :146-153." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=ZHSJ201002035&amp;v=MzE1MjI4NHZSNFQ2ajU0TzN6cXFCdEdGckNVUjdxZlp1Wm1GeWpuVjczT1B5WFlaTEc0SDlITXJZOUdZWVFLREg=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[6]</b>
                                        中华医学会神经病学分会脑血管病学组急性缺血性脑卒中诊治指南撰写组.中国急性缺血性脑卒中诊治指南2010[J].中华神经科杂志, 2010, 43 (2) :146-153.
                                    </a>
                                </li>
                                <li id="17">


                                    <a id="bibliography_7" title="段洪连, 刘美云, 张拥波, 等.缺血性脑卒中常用评估量表及其最新研究进展[J].中国全科医学, 2011, 14 (35) :4018-4021." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=QKYX201135006&amp;v=MTcyNTR6cXFCdEdGckNVUjdxZlp1Wm1GeWpuVjczT05DYlNkckc0SDlEUHFvOUZZb1FLREg4NHZSNFQ2ajU0TzM=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[7]</b>
                                        段洪连, 刘美云, 张拥波, 等.缺血性脑卒中常用评估量表及其最新研究进展[J].中国全科医学, 2011, 14 (35) :4018-4021.
                                    </a>
                                </li>
                                <li id="19">


                                    <a id="bibliography_8" title="金龙, 周昕欣, 马腾.阿托伐他汀联合阿司匹林对颈动脉粥样硬化的影响[J].山东医药, 2014, 54 (17) :58-59." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=SDYY201417023&amp;v=MjQ4MTMzenFxQnRHRnJDVVI3cWZadVptRnlqblY3M09OaW5TZDdHNEg5WE5xSTlIWjRRS0RIODR2UjRUNmo1NE8=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[8]</b>
                                        金龙, 周昕欣, 马腾.阿托伐他汀联合阿司匹林对颈动脉粥样硬化的影响[J].山东医药, 2014, 54 (17) :58-59.
                                    </a>
                                </li>
                                <li id="21">


                                    <a id="bibliography_9" title="赵雪艳.阿托伐他汀对老年急性脑梗死患者血清炎性因子及神经功能的影响[J].中国老年学杂志, 2015, 35 (23) :6788-6790." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=ZLXZ201523066&amp;v=MjYwMDM0dlI0VDZqNTRPM3pxcUJ0R0ZyQ1VSN3FmWnVabUZ5am5WNzNPUHlIVGRMRzRIOVRPckk5RFlvUUtESDg=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[9]</b>
                                        赵雪艳.阿托伐他汀对老年急性脑梗死患者血清炎性因子及神经功能的影响[J].中国老年学杂志, 2015, 35 (23) :6788-6790.
                                    </a>
                                </li>
                                <li id="23">


                                    <a id="bibliography_10" title="王灵红, 章雅妮, 李佳, 等.阿托伐他汀与氢氯吡格雷联合对老年急性脑梗死患者颈动脉粥样硬化斑块的影响[J].中国老年学杂志, 2015, 35 (21) :6113-6114." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=ZLXZ201521050&amp;v=MTYyMjlqNTRPM3pxcUJ0R0ZyQ1VSN3FmWnVabUZ5am5WNzNPUHlIVGRMRzRIOVRPcm85QVpJUUtESDg0dlI0VDY=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[10]</b>
                                        王灵红, 章雅妮, 李佳, 等.阿托伐他汀与氢氯吡格雷联合对老年急性脑梗死患者颈动脉粥样硬化斑块的影响[J].中国老年学杂志, 2015, 35 (21) :6113-6114.
                                    </a>
                                </li>
                                <li id="25">


                                    <a id="bibliography_11" title="方芳, 王雅杰, 陈燕, 等.蛋白标志组早期诊断脑卒中的初步研究[J].中国实验诊断学, 2009, 13 (2) :184-188." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=ZSZD200902020&amp;v=MTU0MzlLREg4NHZSNFQ2ajU0TzN6cXFCdEdGckNVUjdxZlp1Wm1GeWpuVjczT1B6N1Jhckc0SHRqTXJZOUhaSVE=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[11]</b>
                                        方芳, 王雅杰, 陈燕, 等.蛋白标志组早期诊断脑卒中的初步研究[J].中国实验诊断学, 2009, 13 (2) :184-188.
                                    </a>
                                </li>
                                <li id="27">


                                    <a id="bibliography_12" title="夏英凯, 杜怡峰, 韩国哲, 等.急性脑梗死患者血清MCP-1水平变化[J].山东医药, 2016, 56 (1) :79-80." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=SDYY201601032&amp;v=MDg1NDFIODR2UjRUNmo1NE8zenFxQnRHRnJDVVI3cWZadVptRnlqblY3M09OaW5TZDdHNEg5Zk1ybzlHWm9RS0Q=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[12]</b>
                                        夏英凯, 杜怡峰, 韩国哲, 等.急性脑梗死患者血清MCP-1水平变化[J].山东医药, 2016, 56 (1) :79-80.
                                    </a>
                                </li>
                                <li id="29">


                                    <a id="bibliography_13" title="汪翔, 周亮.急性脑梗死患者血清MCP-1的测定和临床研究[J].中华神经医学杂志, 2010, 9 (2) :172-175." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=CJON201002021&amp;v=MTE3ODFIODR2UjRUNmo1NE8zenFxQnRHRnJDVVI3cWZadVptRnlqblY3M09KaWZFWUxHNEg5SE1yWTlIWllRS0Q=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[13]</b>
                                        汪翔, 周亮.急性脑梗死患者血清MCP-1的测定和临床研究[J].中华神经医学杂志, 2010, 9 (2) :172-175.
                                    </a>
                                </li>
                                <li id="31">


                                    <a id="bibliography_14" title="郭庆波, 刘成玉.冠心病病人血清VE-cadherin与hsCRP浓度变化及意义[J].青岛大学医学院学报, 2012, 48 (2) :143-145, 147." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=BATE201202019&amp;v=MDk5OTA1NE8zenFxQnRHRnJDVVI3cWZadVptRnlqblY3M09KeXpmYTdHNEg5UE1yWTlFYllRS0RIODR2UjRUNmo=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[14]</b>
                                        郭庆波, 刘成玉.冠心病病人血清VE-cadherin与hsCRP浓度变化及意义[J].青岛大学医学院学报, 2012, 48 (2) :143-145, 147.
                                    </a>
                                </li>
                                <li id="33">


                                    <a id="bibliography_15" title="习艳兵.急性脑梗塞患者血清MCP-1、VE-cadherin水平与神经功能、颈动脉粥样硬化的相关性[J].海南医学院学报, 2017, 23 (9) :1272-1275." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=HNYY201709032&amp;v=MTAxODJDVVI3cWZadVptRnlqblY3M09MU1BTZDdHNEg5Yk1wbzlHWm9RS0RIODR2UjRUNmo1NE8zenFxQnRHRnI=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[15]</b>
                                        习艳兵.急性脑梗塞患者血清MCP-1、VE-cadherin水平与神经功能、颈动脉粥样硬化的相关性[J].海南医学院学报, 2017, 23 (9) :1272-1275.
                                    </a>
                                </li>
                            </ul>
                            <div style='display: none;' class="zqscroller" >
                                <h4 class="">附加材料</h4>
                                <ul></ul>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
            &nbsp;
            <!--此处有一空格符 勿删-->
        </div>

        
    <div class="content">



        <!--tips start-->
                            <div class="tips">
                    <a href="http://navi.cnki.net/KNavi/JournalDetail?pcode=CJFD&amp;pykm=XXGK" target="_blank">心血管康复医学杂志</a>
                2019,28(04),450-454 DOI:10.3969/j.issn.1008-0074.2019.04.15            </div>
        <!--tips end-->
            <div class="top-title">
                <h1 class="title">
                    <span class="vm"><b>双联抗血小板联合不同剂量阿托伐他汀钙对急性脑梗塞患者血清</b>MCP-1、VE-cadherin<b>水平的影响</b></span>
                                    </h1>

            </div>
                        <h2>
                                <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=au&amp;skey=%E9%83%AD%E5%B0%8F%E5%8F%8C&amp;code=42560799&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">郭小双</a>
                                <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=au&amp;skey=%E5%B0%B9%E6%B3%BD%E5%88%9A&amp;code=42560800&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">尹泽刚</a>
                                <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=au&amp;skey=%E4%B8%A5%E5%86%AC%E6%A2%85&amp;code=42560801&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">严冬梅</a>
                </h2>
                    <h2>
                    <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=in&amp;skey=%E5%9B%9B%E5%B7%9D%E7%9C%81%E5%85%AB%E4%B8%80%E5%BA%B7%E5%A4%8D%E4%B8%AD%E5%BF%83(%E5%9B%9B%E5%B7%9D%E7%9C%81%E5%BA%B7%E5%A4%8D%E5%8C%BB%E9%99%A2)%E7%A5%9E%E7%BB%8F%E5%BA%B7%E5%A4%8D%E7%A7%91&amp;code=1696124&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">四川省八一康复中心(四川省康复医院)神经康复科</a>
                    <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=in&amp;skey=%E6%88%90%E9%83%BD%E5%86%9B%E5%8C%BA%E6%80%BB%E5%8C%BB%E9%99%A2&amp;code=1018311&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">成都军区总医院</a>
                    <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=in&amp;skey=%E6%88%90%E9%83%BD%E5%B8%82%E7%AC%AC%E5%8D%81%E4%BA%BA%E6%B0%91%E5%8C%BB%E9%99%A2&amp;code=0216132&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">成都市第十人民医院</a>
            </h2>

        
<div class="link">
    <a id="aexport" class="icon icon-output"  onclick="" href="javascript:void(0);"><i></i>导出/参考文献</a>
    
    <span class="shareBoard" onmouseover="$('#sharedet').show();$('#this').addClass('shareBoardCUR')" onmouseout="$('#sharedet').hide();$('#this').removeClass('shareBoardCUR')">
        <a class="icon icon-share" href="#"><i></i>分享<em></em></a>
        <ul class="shareHide" id="sharedet" style="display: none;">
            <li><a title="复制链接" class="copy" onclick="" href="#"><i></i>复制链接</a></li>
            <li><a title="分享到新浪微博" class="xl" onclick="" href="javascript:common.ShareAction('xl');"><i></i>新浪微博</a></li>
            <li>
                <a title="分享到微信" class="wx" onclick="" href="#"><i></i>微信扫一扫</a>
                <div class="qrcode"><img src='' alt='' /></div>
            </li>
        </ul>

    </span>
    
    <a id="RefTrack" title="创建引文跟踪" class="icon icon-track" onclick="" href="javascript:void(0);"> <i></i>创建引文跟踪 </a>
    <a id="ashoucang" title="收藏" class="icon icon-favor" onclick="" href="javascript:void(0);"><i></i>收藏</a>
    <a class="icon icon-print" onclick="window.print();" href="javascript:void(0);"><i></i>打印</a>
    
    <!--版本切换 end-->
</div>
                            <div class="data" id="a_abstract">
                <span class="keys">摘<span style="font-family: 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;</span>要：</span>
                <p><b>目的</b>:探讨双联抗血小板治疗联合不同剂量阿托伐他汀钙对急性脑梗塞 (ACI) 患者血清单核细胞趋化因子 (MCP) -1、血管内皮细胞钙黏蛋白 (VE-cadherin) 水平的影响。<b>方法</b>:2016年至2017年在我院就诊的119例ACI患者被随机分为阿托伐他汀常规剂量组 (常规剂量组, 61例) 和阿托伐他汀大剂量组 (大剂量组, 58例, 40mg, 1次/d) , 两组均接受常规和阿司匹林+氯吡格雷治疗, 两组均治疗30d。治疗前后测量比较两组NIHSS、hsCRP、TNF-α、IL-8、MCP-1、VE-cadherin水平、颈动脉粥样硬化斑块面积和IMT, 以及治疗中的不良反应。<b>结果</b>:与治疗前比较, 两组治疗15d、30d后NIHSS评分均显著降低, 且30d的显著低于15d的, <i>P</i>均=0.001;与常规剂量组比较, 大剂量组治疗15d、30d后的NIHSS评分[15d: (5.32±1.63) 分比 (4.13±1.25) 分]降低更显著, <i>P</i>均=0.001。与常规剂量组比较, 治疗30d后大剂量组血清hsCRP[ (9.37±1.85) mg/L比 (6.35±1.94) mg/L]、TNF-α[ (10.15±2.47) μg/L比 (7.44±1.94) μg/L]、IL-8[ (20.35±4.48) μmol/L比 (15.14±3.61) μmol/L]、MCP-1[ (234.54±32.53) ng/L比 (185.46±29.47) ng/L]、VE-cadherin [ (5.32±0.49) mg/L比 (4.18±0.54) mg/L]水平、斑块面积[ (17.25±3.14) mm<sup>2</sup>比 (14.13±2.07) mm<sup>2</sup>]和IMT[ (1.08±0.25) mm比 (0.85±0.17) mm]降低更显著, <i>P</i>均=0.001。两组不良反应发生率无显著差异。<b>结论</b>:大剂量阿托伐他汀联合双联抗血小板治疗可显著降低血清MCP-1和VE-cadherin水平, 改善脑功能, 并未增加不良反应率, 值得临床推广。</p>
            </div>
                    <div class="data" id="a_keywords">
                <span class="keys">关键词：</span>
                <p>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=%E8%84%91%E6%A2%97%E6%AD%BB&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">脑梗死;</a>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=%E6%B0%AF%E5%90%A1%E6%A0%BC%E9%9B%B7&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">氯吡格雷;</a>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=%E9%98%BF%E6%89%98%E4%BC%90%E4%BB%96%E6%B1%80&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">阿托伐他汀;</a>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=%E5%89%82%E9%87%8F%E6%95%88%E5%BA%94%E5%85%B3%E7%B3%BB%2C%20%E8%8D%AF%E7%89%A9&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">剂量效应关系, 药物;</a>
                </p>
            </div>
        
        <!--brief start-->
        
            <div class="brief">
                    <p>
                                            </p>
                                    <p><b>收稿日期：</b>2018-02-06</p>

            </div>
                    <h1>Influence of dual antiplatelet therapy combined different dose of atorvastatin calcium on serum levels of MCP-1 and VE-cadherin in patients with acute cerebral infarction</h1>
                    <h2>
                    <span>GUO Xiao-shuang</span>
                    <span>YIN Ze-gang</span>
                    <span>YAN Dong-mei</span>
            </h2>
                    <h2>
                    <span>Department of Neurological Rehabilitation, Sichuan 81 Rehabilitation Center</span>
            </h2>
                            <div class="data" id="a_abstractEN">
                <span class="keys">Abstract：</span>
                <p><b>Objective</b>:To explore influence of dual antiplatelet therapy combined different dose of atorvastatin calcium on serum levels of monocyte chemoattractant protein (MCP) -1 and vascular endothelial cadherin (VE-cadherin) in patients with acute cerebral infarction atorvastatin routine dose group (ACI) . <b>Methods</b>:A total of 119 ACI patients admitted in our hospital from 2016 to 2017 were randomly divided into atorvastatin routine dose group (n=61) and large dose group (n=58, 40 mg, once/d) , both groups received routine treatment and aspirin + clopidogrel for 30 d. NIHSS, serum levels of hsCRP, TNF-α, IL-8, MCP-1 and VE-cadherin, carotid atherosclerotic plaque size and IMT before and after treatment, and incidence of adverse reactions were measured and compared between two groups. <b>Results</b>:Compared with before treatment, there was significant reduction in NIHSS score after 15 d and 30 d in two groups, and those of 30 d were significantly lower than those of 15 d, <i>P</i>=0.001 all; compared with routine dose group after 15 d and 30 d, there was significant reduction in NIHSS score [15 d: (5.32±1.63) scores vs. (4.13±1.25) scores] in large dose group, <i>P</i>=0.001; Compared with routine dose group after 30 d, there were significant reductions in serum levels of hsCRP[ (9.37±1.85) mg/L vs. (6.35±1.94) mg/L], TNF-α[ (10.15±2.47) μg/L vs. (7.44±1.94) μg/L], IL-8[ (20.35±4.48) μmol/L vs. (15.14±3.61) μmol/L], MCP-1 [ (234.54±32.53) ng/L vs. (185.46± 29.47) ng/L], VE-cadherin [ (5.32±0.49) mg/L vs. (4.18±0.54) mg/L], plaque size [ (17.25±3.14) mm<sup>2</sup> vs. (14.13±2.07) mm<sup>2</sup>] and IMT[ (1.08± 0.25) mm vs. (0.85±0.17) mm] in large dose group, <i>P</i>=0.001 all. There was no significant difference in incidence rate of adverse reaction between two groups. <b>Conclusion</b>:Large dose atorvastatin combined dual antiplatelet therapy can significantly reduce serum levels of MCP-1 and VE-cadherin, improve brain function without increasing incidence rate of adverse reactions.</p>
            </div>
                    <div class="data" id="a_keywordsEN">
                <span class="keys">Keyword：</span>
                <p>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=Brain%20infarction&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">Brain infarction;</a>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=Clopidogrel&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">Clopidogrel;</a>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=Atorvastatin&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">Atorvastatin;</a>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=Dose-response%20relationship%2C%20drug&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">Dose-response relationship, drug;</a>
                </p>
            </div>
                    <div class="brief">
                
                    <p>
                                            </p>
                                    <p><b>Received：</b> 2018-02-06</p>
                            </div>


        <!--brief start-->
                        <div class="p1">
                    <p id="35">急性脑梗死指脑部血液循环突然中断, 供血区域脑组织因缺血、缺氧出现局限性缺血性坏死和软化, 具有发病率高、病死率高和致残率高等特点, 近年来, 随着生活方式的改变、生活水平的提高和老龄化的加速, 急性脑梗死发病率呈上升趋势<citation id="69" type="reference"><link href="5" rel="bibliography" /><sup>[<a class="sup">1</a>]</sup></citation>。急性脑梗死发病的病理生理机制复杂, 多种炎症因子、免疫因子、黏附因子均参与其病情发生发展, 在颈动脉粥样硬化不稳定斑块的基础上血栓形成是发病的重要原因<citation id="70" type="reference"><link href="7" rel="bibliography" /><sup>[<a class="sup">2</a>]</sup></citation>。阿司匹林是常用的抗血小板药物, 但部分患者存在阿司匹林抵抗现象, 氯吡格雷是选择性的二磷酸腺苷 (ADP) 抑制剂, 与阿司匹林抗血小板作用机制不同, 联合应用具有协同作用<citation id="71" type="reference"><link href="9" rel="bibliography" /><sup>[<a class="sup">3</a>]</sup></citation>。阿托伐他汀钙属于羟甲基戊二酸单酰辅酶A (HMG-CoA) 还原酶抑制剂, 具有调脂、改善微循环、抗炎、抗氧化、神经保护等多种功效, 可显著改善脑梗死患者病情<citation id="72" type="reference"><link href="11" rel="bibliography" /><sup>[<a class="sup">4</a>]</sup></citation>。本研究观察了在氯吡格雷和阿司匹林双联抗血小板的基础上给予不同剂量阿托伐他汀治疗急性脑梗死的临床效果及对患者血清单核细胞趋化因子-1 (MCP-1) 和血管内皮细胞钙黏蛋白 (VE-cadherin) 水平的影响, 旨在探讨阿托伐他汀治疗急性脑梗死的优选剂量, 现将结果报告如下。</p>
                </div>
                <h3 id="36" name="36" class="anchor-tag"><b>1 资料与方法</b></h3>
                <h4 class="anchor-tag" id="37" name="37">1.1 一般资料</h4>
                <div class="p1">
                    <p id="38">选择2016年1月至2017年3月在我院就诊的急性脑梗死患者119例作为研究对象, 采用随机数字表法, 患者被分为常规剂量组和大剂量组。常规剂量组61例, 其中男39例, 女22例;年龄49～75 (62.38±8.74) 岁;病程 (19.49±10.25) h;美国国立卫生院神经功能缺损评分 (NIHSS, 7.49±2.18) 分;个人史:吸烟24例, 饮酒31例;合并疾病:糖尿病37例, 高血压34例, 血脂升高52例。大剂量组58例, 其中男40例, 女18例;年龄50～75 (63.75±8.93) 岁;病程 (20.81±11.49) h;NIHSS评分 (7.83±2.42) 分;个人史:吸烟21例, 饮酒30例, 合并疾病:糖尿病36例, 高血压35例, 血脂升高50例。两组患者性别、年龄、病程、NIHSS评分、个人史、合并疾病等基础资料相比较差异均无统计学意义 (<i>P</i>均&gt;0.05) , 具有可比性。纳入标准:综合临床症状、体征和影像学检查符合急性脑梗死的诊断标准<citation id="73" type="reference"><link href="13" rel="bibliography" /><sup>[<a class="sup">5</a>]</sup></citation>;年龄18～80岁, 发病至入院时间&lt;24h;无溶栓禁忌证或家属拒绝接受溶栓治疗;患者及家属对研究知情并签署知情同意书。排除标准:年龄&gt;80岁;合并严重心、肝、肾、凝血机制障碍者;近期有活动性出血者;合并感染性、自体免疫性、恶性肿瘤、心肌梗死等疾病;既往有脑梗死史者;入组前4周服用过他汀类、免疫抑制剂、激素等药物者;精神疾病者;拟纳入其他临床研究者。</p>
                </div>
                <h4 class="anchor-tag" id="39" name="39">1.2 治疗方法</h4>
                <div class="p1">
                    <p id="40">常规剂量组患者参照《中国急性缺血性脑卒中诊治指南》<citation id="74" type="reference"><link href="15" rel="bibliography" /><sup>[<a class="sup">6</a>]</sup></citation>制定治疗方案, 包括吸氧与呼吸支持、心电监测、体温控制、控制血压、纠正高 (低) 血糖、营养支持、营养脑细胞等治疗, 同时给予阿司匹林肠溶片 (拜耳医药保健有限公司, 注册证号:国药准字J20080078, 规格:100mg) 100mg口服, 1次/d, 硫酸氢氯吡格雷片 (赛诺菲杭州制药有限公司, 批准文号:国药准字H20056410, 规格:75mg) 75mg口服, 1次/d, 阿托伐他汀钙 (辉瑞制药有限公司, 注册证号:国药准字J20120050, 规格:10mg) 20mg口服, 1次/d。大剂量组给予阿托伐他汀钙40mg口服, 1次/d, 余治疗措施同常规剂量组。两组均以30d为1疗程。</p>
                </div>
                <h4 class="anchor-tag" id="41" name="41">1.3 观察指标</h4>
                <div class="p1">
                    <p id="42">①两组治疗前后采用美国国立卫生院神经功能缺损评分 (NIHSS) 评估病情严重程度<citation id="75" type="reference"><link href="17" rel="bibliography" /><sup>[<a class="sup">7</a>]</sup></citation>;②治疗前后抽取患者空腹静脉血, 采用免疫比浊法检测血清高敏C反应蛋白 (hsCRP) 水平, 采用酶联免疫吸附法检测血清白细胞介素-8 (IL-8) 、肿瘤坏死因子α (TNF-α) 、MCP-1、VE-cadherin水平;③治疗前后采用彩色超声多普勒检测患者颈动脉粥样硬化斑块面积和颈动脉内膜中层厚度 (IMT) ;④观察两组治疗过程中不良反应发生情况。</p>
                </div>
                <h4 class="anchor-tag" id="43" name="43">1.4 统计学方法</h4>
                <div class="p1">
                    <p id="44">采用SPSS 23.0进行统计学数据分析。计量资料以均数±标准差 (<image id="85" type="formula" href="images/XXGK201904015_08500.jpg" display="inline" placement="inline"><alt></alt></image>±s) 表示, 比较采用<i>t</i>检验, 计数资料以百分率表示, 比较采用<i>χ</i><sup>2</sup>检验。<i>P</i>&lt;0.05为差异有统计学意义。</p>
                </div>
                <h3 id="46" name="46" class="anchor-tag"><b>2 结 果</b></h3>
                <h4 class="anchor-tag" id="47" name="47">2.1 两组治疗前后NIHSS评分相比较</h4>
                <div class="p1">
                    <p id="48">两组治疗前NIHSS评分相比较无显著性差异 (<i>P</i>=0.418) 。随着时间推移, 两组NIHSS评分均显著下降 (<i>P</i>均=0.001) ;治疗15d、30d时大剂量组NIHSS评分均显著低于常规剂量组 (<i>P</i>均=0.001) 。见表1。</p>
                </div>
                <h4 class="anchor-tag" id="49" name="49">2.2 两组治疗前、治疗30d后炎症因子水平相比较</h4>
                <div class="p1">
                    <p id="50">两组治疗前血清hsCRP、TNF-α、IL-8水平相比较差异均无统计学意义 (<i>P</i>均&gt;0.05) ;与治疗前比较, 两组治疗30d后血清hsCRP、TNF-α和IL-8水平均显著降低 (<i>P</i>均=0.001) , 且大剂量组比常规剂量组降低更显著 (<i>P</i>均=0.001) 。见表2。</p>
                </div>
                <div class="area_img" id="51">
                    <p class="img_tit"><b>表</b>1 <b>两组治疗前后</b>NIHSS<b>评分相比较</b> (<image id="86" type="formula" href="images/XXGK201904015_08600.jpg" display="inline" placement="inline"><alt></alt></image>±s)  <a class="downexcel" onclick="DownLoadReportExcel(this)">导出到EXCEL</a></p>
                    <p class="img_tit"></p>
                    <p class="img_note"></p>
                    <table id="51" border="1"><tr><td>组别</td><td>例数</td><td>治疗前</td><td>治疗15d<br /> (分) </td><td>治疗30d<br /> (分) </td><td><i>F</i>/<i>P</i></td><td>治疗前与治疗<br />15d比较 <i>P</i></td><td>治疗前与治疗<br />30d比较<i>P</i></td><td>治疗15d与治疗<br />30d比较<i>P</i></td></tr><tr><td><br />常规剂量组</td><td>61</td><td>7.49±2.14</td><td>5.32±1.63<sup>**</sup></td><td>3.08±1.25<sup>**▲▲</sup></td><td>101.128/0.001</td><td>0.001</td><td>0.001</td><td>0.001</td></tr><tr><td><br />大剂量组</td><td>58</td><td>7.83±2.42</td><td>4.13±1.25<sup>**△△</sup></td><td>1.85±0.23<sup>**△△▲▲</sup></td><td>212.106/0.001</td><td>0.001</td><td>0.001</td><td>0.001</td></tr><tr><td><br /><i>t</i>/<i>P</i></td><td></td><td>0.813/0.418</td><td>4.453/0.001</td><td>7.375/0.001</td><td></td><td></td><td></td><td></td></tr></table>
                    <form name="form" action="/kxreader/Detail/DownloadReportExcel" method="POST" style="display:inline">
                        <input type="hidden" name="hidTable" value="" />
                        <input type="hidden" name="hidFileName" value="" />
                    </form>
                    <p class="img_note">注:NIHSS:美国国立卫生院神经功能缺损评分。与治疗前比较*<i>P</i>&lt;0.05, **<i>P</i>&lt;0.01;与常规剂量组比较△<i>P</i>&lt;0.05, △△<i>P</i>&lt;0.01;与治疗15d比较▲<i>P</i>&lt;0.05, ▲▲<i>P</i>&lt;0.01。下表同。</p>
                    <p class="img_note"></p>
                </div>
                <div class="area_img" id="53">
                    <p class="img_tit"><b>表</b>2 <b>两组治疗前、治疗</b>30d<b>后炎症因子水平相比较</b> (<image id="87" type="formula" href="images/XXGK201904015_08700.jpg" display="inline" placement="inline"><alt></alt></image>±s)  <a class="downexcel" onclick="DownLoadReportExcel(this)">导出到EXCEL</a></p>
                    <p class="img_tit"></p>
                    <p class="img_note"></p>
                    <table id="53" border="1"><tr><td><br />组别</td><td>高敏C反应蛋白<br /> (mg/L) </td><td>肿瘤坏死因子α<br /> (μg/L) </td><td>白介素-8<br /> (μmol/L) </td></tr><tr><td><br />常规剂量组 (61例) </td><td></td><td></td><td></td></tr><tr><td><br /> 治疗前</td><td>17.54±2.89</td><td>16.54±2.62</td><td>29.82±5.69</td></tr><tr><td><br /> 治疗30d</td><td>9.37±1.85<sup>**</sup></td><td>10.15±2.47<sup>**</sup></td><td>20.35±4.48<sup>**</sup></td></tr><tr><td><br /><i>t</i>/<i>P</i></td><td>18.596/0.001</td><td>13.860/0.001</td><td>10.213/0.001</td></tr><tr><td><br />大剂量组 (58例) </td><td></td><td></td><td></td></tr><tr><td><br /> 治疗前</td><td>18.02±3.47</td><td>16.83±2.79</td><td>30.64±5.93</td></tr><tr><td><br /> 治疗30d</td><td>6.35±1.94<sup>**△△</sup></td><td>7.44±1.94<sup>**△△</sup></td><td>15.14±3.61<sup>**△△</sup></td></tr><tr><td><br /><i>t</i>/<i>P</i></td><td>22.356/0.001</td><td>21.044/0.001</td><td>17.003/0.001</td></tr><tr><td><br />组间治疗前<i>t</i>/<i>P</i></td><td>0.822/0.413</td><td>0.585/0.560</td><td>0.770/0.443</td></tr><tr><td><br />组间治疗后<i>t</i>/<i>P</i></td><td>8.693/0.001</td><td>6.633/0.001</td><td>6.964/0.001</td></tr></table>
                    <form name="form" action="/kxreader/Detail/DownloadReportExcel" method="POST" style="display:inline">
                        <input type="hidden" name="hidTable" value="" />
                        <input type="hidden" name="hidFileName" value="" />
                    </form>
                    <p class="img_note"></p>
                    <p class="img_note"></p>
                </div>
                <h4 class="anchor-tag" id="55" name="55">2.3 两组治疗前、治疗30d后MCP-1和VE-cadherin水平相比较</h4>
                <div class="p1">
                    <p id="56">两组治疗前血清MCP-1和VE-cadherin水平相比较差异均无统计学意义 (<i>P</i>均&gt;0.05) ;与治疗前比较, 两组治疗30d后血清MCP-1和VE-cadherin水平均显著降低 (<i>P</i>均=0.001) , 且大剂量组比常规剂量组降低更显著 (<i>P</i>均=0.001) 。见表3。</p>
                </div>
                <h4 class="anchor-tag" id="57" name="57">2.4 两组治疗前、治疗30d后颈动脉粥样硬化指标相比较</h4>
                <div class="p1">
                    <p id="58">两组治疗前动脉粥样硬化斑块面积和IMT相比较差异均无统计学意义 (<i>P</i>均&gt;0.05) ;与治疗前比较, 两组治疗30d后动脉粥样硬化斑块面积和IMT均显著降低 (<i>P</i>均=0.001) , 且大剂量组比常规剂量组降低更显著 (<i>P</i>均=0.001) 。见表4。</p>
                </div>
                <div class="area_img" id="59">
                                            <p class="img_tit">
                                                <b>表</b>3 <b>两组治疗前、治疗</b>30d<b>后</b>MCP-1<b>和</b>VE-cadherin<b>水平相比较</b> (<image id="88" type="formula" href="images/XXGK201904015_08800.jpg" display="inline" placement="inline"><alt></alt></image>±s) 
                                                
                                                &nbsp;&nbsp;
                                                <a class="btn-zoomin" href="Detail/GetImg?filename=images/XXGK201904015_05900.jpg&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!"></a>
                                                <a class="table downimg" data-tablename="Detail/GetImg?filename=images/XXGK201904015_05900.jpg&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">下载原表</a>
                                            </p>
                                    <a class="zoom-in" href="Detail/GetImg?filename=images/XXGK201904015_05900.jpg&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <img alt="表3 两组治疗前、治疗30d后MCP-1和VE-cadherin水平相比较 (&#177;s)" src="Detail/GetImg?filename=images/XXGK201904015_05900.jpg&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" />
                                    </a>
                                <p class="img_note">注:MCP-1:单核细胞趋化因子-1, VE-cadherin:血管内皮细胞钙黏蛋白。</p>

                </div>
                <div class="area_img" id="61">
                                            <p class="img_tit">
                                                <b>表</b>4 <b>两组治疗前、治疗</b>30d<b>后颈动脉粥样硬化指标相比较</b> (<image id="89" type="formula" href="images/XXGK201904015_08900.jpg" display="inline" placement="inline"><alt></alt></image>±s) 
                                                
                                                &nbsp;&nbsp;
                                                <a class="btn-zoomin" href="Detail/GetImg?filename=images/XXGK201904015_06100.jpg&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!"></a>
                                                <a class="table downimg" data-tablename="Detail/GetImg?filename=images/XXGK201904015_06100.jpg&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">下载原表</a>
                                            </p>
                                    <a class="zoom-in" href="Detail/GetImg?filename=images/XXGK201904015_06100.jpg&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <img alt="表4 两组治疗前、治疗30d后颈动脉粥样硬化指标相比较 (&#177;s)" src="Detail/GetImg?filename=images/XXGK201904015_06100.jpg&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" />
                                    </a>

                </div>
                <h4 class="anchor-tag" id="63" name="63">2.5 两组治疗过程中不良反应发生率相比较</h4>
                <div class="p1">
                    <p id="64">常规剂量组治疗过程中出现胃肠道反应4例, 转氨酶升高5例, 牙龈出血2例, 血尿1例, 不良反应发生率19.67% (12/61) ;大剂量组治疗过程中出现胃肠道反应5例, 转氨酶升高6例, 牙龈出血3例, 血尿1例, 不良反应发生率25.86% (15/58) , 两组不良反应发生率相比较差异无统计学意义 (<i>χ</i><sup>2</sup>=0.649, <i>P</i>=0.420) 。</p>
                </div>
                <h3 id="65" name="65" class="anchor-tag"><b>3 讨 论</b></h3>
                <div class="p1">
                    <p id="66">阿托伐他汀为新型他汀类药物, 可竞争性抑制胆固醇合成过程中的限速酶HMG-CoA还原酶, 阻断内源性胆固醇合成, 降低胆固醇水平, 同时可抑制巨噬细胞的酶作用和炎症因子, 稳定粥样斑块<citation id="76" type="reference"><link href="19" rel="bibliography" /><sup>[<a class="sup">8</a>]</sup></citation>。研究显示, 除调脂作用外, 阿托伐他汀亦可降低急性脑梗死患者炎性反应, 抑制血栓形成, 改善脑供血, 促进神经恢复<citation id="77" type="reference"><link href="21" rel="bibliography" /><sup>[<a class="sup">9</a>]</sup></citation>。氯吡格雷为新型抗血小板药物, 可选择性、不可逆地与血小板表面的ADP受体P2Y12结合, 竞争性抑制血小板聚集, 除抗血小板作用外, 氯吡格雷尚可抑制动脉粥样硬化的炎症进程, 减少斑块形成, 阿托伐他汀联合氯吡格雷可增强血脂调控的效率<citation id="78" type="reference"><link href="23" rel="bibliography" /><sup>[<a class="sup">10</a>]</sup></citation>。研究显示, 阿托伐他汀调脂作用具有量效依赖关系, 大剂量阿托伐他汀对LDL-C的清除效果优于低剂量, 对急性脑梗死患者NIHSS评分的改善效果优于低剂量<citation id="79" type="reference"><link href="7" rel="bibliography" /><sup>[<a class="sup">2</a>]</sup></citation>。本研究结果显示, 大剂量组治疗15d、治疗30d时大剂量组NIHSS评分均显著低于常规剂量组, 结果提示, 大剂量阿托伐他汀联合氯吡格雷可更好地改善急性脑梗死患者神经功能。</p>
                </div>
                <div class="p1">
                    <p id="67">急性脑梗死的病理生理过程十分复杂, 能量耗竭、氧化应激、钙超载、神经元凋亡调控基因、炎症反应等均在脑组织缺血缺氧损伤中发挥重要作用, MCP-1属于C-C趋化因子亚族, 正常脑组织极少表达MCP-1, 在急性缺血性损伤时脑内神经元、巨噬细胞、内皮细胞、活化的小胶质细胞及星形胶质细胞等多种细胞表达MCP-1, 诱导、趋化和激活单核巨噬细胞, 引发炎症瀑布反应, hsCRP、TNF-α、IL-8等炎症因子分泌增加, 参与缺血再灌注脑损伤病理过程<citation id="80" type="reference"><link href="25" rel="bibliography" /><sup>[<a class="sup">11</a>]</sup></citation>。研究显示, 敲除MCP-1基因可降低大脑中动脉闭塞动物模型炎症因子表达, 减轻脑损伤, 减少脑梗死体积<citation id="81" type="reference"><link href="27" rel="bibliography" /><sup>[<a class="sup">12</a>]</sup></citation>。临床研究显示, 急性脑梗死患者血清MCP-1水平显著升高, 且与病情严重程度呈正相关, MCP-1水平变化对急性脑梗死的预后具有预测价值<citation id="82" type="reference"><link href="29" rel="bibliography" /><sup>[<a class="sup">13</a>]</sup></citation>。VE-cadherin是内皮细胞特异性钙黏蛋白, 在动脉粥样硬化过程中, 可增加血管通透性并促进炎症细胞在血管内皮黏附, 促进动脉粥样硬化的发生发展<citation id="83" type="reference"><link href="31" rel="bibliography" /><sup>[<a class="sup">14</a>]</sup></citation>。习艳兵研究<citation id="84" type="reference"><link href="33" rel="bibliography" /><sup>[<a class="sup">15</a>]</sup></citation>显示, VE-cadherin水平升高可造成动脉粥样硬斑块性质改变, 稳定性下降, 脑梗死患者血清VE-cadherin水平显著升高。因此, 降低MCP-1和VE-cadherin水平可能成为药物治疗急性脑梗死的新靶点。本研究结果显示, 大剂量组治疗后血清MCP-1、VE-cadherin、hsCRP、TNF-α、IL-8水平、动脉粥样硬化斑块面积和IMT均显著低于常规剂量组, 提示大剂量阿托伐他汀联合氯吡格雷可增强对MCP-1和VE-cadherin等水平的抑制效果, 减轻炎症反应, 稳定粥样斑块, 有利于抑制脑缺血再灌注炎症损伤。本研究结果显示, 两组患者不良反应相比较差异无统计学意义, 提示大剂量阿托伐他汀联合氯吡格雷安全性良好。</p>
                </div>
                <div class="p1">
                    <p id="68">综上所述, 大剂量阿托他汀联合氯吡格雷可增强对MCP-1和VE-cadherin等水平的抑制效果, 降低炎症反应对脑组织的损伤, 改善脑功能, 未增加不良反应发生率, 安全性好, 值得临床推广应用。</p>
                </div>

        <!--brief end-->
        
        <!--conten left  end-->
        <!--增强附件-->
        

        <!--reference start-->
            <div class="reference anchor-tag" id="a_bibliography">
                    <h3>参考文献</h3>
                                        <p id="5">
                            <a id="bibliography_1" target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=LNXG201403005&amp;v=MTg0ODNUYWJHNEg5WE1ySTlGWVlRS0RIODR2UjRUNmo1NE8zenFxQnRHRnJDVVI3cWZadVptRnlqblY3M09LU1A=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[1]</b>申丽红, 梁小乐, 高旭光.急性脑梗死患者微栓子与颈动脉粥样硬化斑块的相关性研究[J].中华老年心脑血管病杂志, 2014, 16 (3) :237-239.
                            </a>
                        </p>
                        <p id="7">
                            <a id="bibliography_2" target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=LNXG201408020&amp;v=MDMzNDdmWnVabUZ5am5WNzNPS1NQVGFiRzRIOVhNcDQ5SFpJUUtESDg0dlI0VDZqNTRPM3pxcUJ0R0ZyQ1VSN3E=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[2]</b>张全新.大剂量阿托伐他汀治疗急性脑梗死患者的疗效观察[J].中华老年心血管病杂志, 2014, 16 (8) :843-845.
                            </a>
                        </p>
                        <p id="9">
                            <a id="bibliography_3" target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=YXZS201519065&amp;v=MjQ5NDJDVVI3cWZadVptRnlqblY3M09QRFhSZmJHNEg5VE5wbzlEWVlRS0RIODR2UjRUNmo1NE8zenFxQnRHRnI=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[3]</b>李娟.氯吡格雷联合拜阿司匹林在急性脑梗死患者抗血小板聚集中的应用[J].医学综述, 2015, 21 (19) :3616-3618.
                            </a>
                        </p>
                        <p id="11">
                            <a id="bibliography_4" target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=LNXG201609012&amp;v=MzE1MTJwbzlFWm9RS0RIODR2UjRUNmo1NE8zenFxQnRHRnJDVVI3cWZadVptRnlqblY3M09LU1BUYWJHNEg5Zk0=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[4]</b>杜文秀, 李艳艳, 史路遥, 等.阿托伐他汀钙对急性脑梗死患者血浆S100β和高迁移率族蛋白1水平的影响[J].中华老年心脑血管病杂志, 2016, 18 (9) :938-942.
                            </a>
                        </p>
                        <p id="13">
                            <a id="bibliography_5" target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=ZHSJ606.025&amp;v=MTA5NjdmYnVkdUZTem5WUT09UHlYWVpMVzRHTS9NcllvcVllc01EUTR4enhZUzcweCtRSHZyMzMwM2ViQ1VSYnU=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[5]</b>中华医学会全国第四届脑血管病学术会议组.各类脑血管疾病诊断要点[J].中华神经科杂志, 1996, 29 (6) :379.
                            </a>
                        </p>
                        <p id="15">
                            <a id="bibliography_6" target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=ZHSJ201002035&amp;v=MDg4NDlqNTRPM3pxcUJ0R0ZyQ1VSN3FmWnVabUZ5am5WNzNPUHlYWVpMRzRIOUhNclk5R1lZUUtESDg0dlI0VDY=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[6]</b>中华医学会神经病学分会脑血管病学组急性缺血性脑卒中诊治指南撰写组.中国急性缺血性脑卒中诊治指南2010[J].中华神经科杂志, 2010, 43 (2) :146-153.
                            </a>
                        </p>
                        <p id="17">
                            <a id="bibliography_7" target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=QKYX201135006&amp;v=MjgzOThRS0RIODR2UjRUNmo1NE8zenFxQnRHRnJDVVI3cWZadVptRnlqblY3M09OQ2JTZHJHNEg5RFBxbzlGWW8=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[7]</b>段洪连, 刘美云, 张拥波, 等.缺血性脑卒中常用评估量表及其最新研究进展[J].中国全科医学, 2011, 14 (35) :4018-4021.
                            </a>
                        </p>
                        <p id="19">
                            <a id="bibliography_8" target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=SDYY201417023&amp;v=MjE5OTMzenFxQnRHRnJDVVI3cWZadVptRnlqblY3M09OaW5TZDdHNEg5WE5xSTlIWjRRS0RIODR2UjRUNmo1NE8=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[8]</b>金龙, 周昕欣, 马腾.阿托伐他汀联合阿司匹林对颈动脉粥样硬化的影响[J].山东医药, 2014, 54 (17) :58-59.
                            </a>
                        </p>
                        <p id="21">
                            <a id="bibliography_9" target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=ZLXZ201523066&amp;v=MTg2MDk5VE9ySTlEWW9RS0RIODR2UjRUNmo1NE8zenFxQnRHRnJDVVI3cWZadVptRnlqblY3M09QeUhUZExHNEg=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[9]</b>赵雪艳.阿托伐他汀对老年急性脑梗死患者血清炎性因子及神经功能的影响[J].中国老年学杂志, 2015, 35 (23) :6788-6790.
                            </a>
                        </p>
                        <p id="23">
                            <a id="bibliography_10" target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=ZLXZ201521050&amp;v=MDU0NzBUT3JvOUFaSVFLREg4NHZSNFQ2ajU0TzN6cXFCdEdGckNVUjdxZlp1Wm1GeWpuVjczT1B5SFRkTEc0SDk=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[10]</b>王灵红, 章雅妮, 李佳, 等.阿托伐他汀与氢氯吡格雷联合对老年急性脑梗死患者颈动脉粥样硬化斑块的影响[J].中国老年学杂志, 2015, 35 (21) :6113-6114.
                            </a>
                        </p>
                        <p id="25">
                            <a id="bibliography_11" target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=ZSZD200902020&amp;v=MTExOTZxQnRHRnJDVVI3cWZadVptRnlqblY3M09QejdSYXJHNEh0ak1yWTlIWklRS0RIODR2UjRUNmo1NE8zenE=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[11]</b>方芳, 王雅杰, 陈燕, 等.蛋白标志组早期诊断脑卒中的初步研究[J].中国实验诊断学, 2009, 13 (2) :184-188.
                            </a>
                        </p>
                        <p id="27">
                            <a id="bibliography_12" target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=SDYY201601032&amp;v=Mjg5NjdmWnVabUZ5am5WNzNPTmluU2Q3RzRIOWZNcm85R1pvUUtESDg0dlI0VDZqNTRPM3pxcUJ0R0ZyQ1VSN3E=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[12]</b>夏英凯, 杜怡峰, 韩国哲, 等.急性脑梗死患者血清MCP-1水平变化[J].山东医药, 2016, 56 (1) :79-80.
                            </a>
                        </p>
                        <p id="29">
                            <a id="bibliography_13" target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=CJON201002021&amp;v=MjAwMzlPSmlmRVlMRzRIOUhNclk5SFpZUUtESDg0dlI0VDZqNTRPM3pxcUJ0R0ZyQ1VSN3FmWnVabUZ5am5WNzM=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[13]</b>汪翔, 周亮.急性脑梗死患者血清MCP-1的测定和临床研究[J].中华神经医学杂志, 2010, 9 (2) :172-175.
                            </a>
                        </p>
                        <p id="31">
                            <a id="bibliography_14" target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=BATE201202019&amp;v=MDY2NDNVUjdxZlp1Wm1GeWpuVjczT0p5emZhN0c0SDlQTXJZOUViWVFLREg4NHZSNFQ2ajU0TzN6cXFCdEdGckM=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[14]</b>郭庆波, 刘成玉.冠心病病人血清VE-cadherin与hsCRP浓度变化及意义[J].青岛大学医学院学报, 2012, 48 (2) :143-145, 147.
                            </a>
                        </p>
                        <p id="33">
                            <a id="bibliography_15" target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=HNYY201709032&amp;v=MDMxMjhIOWJNcG85R1pvUUtESDg0dlI0VDZqNTRPM3pxcUJ0R0ZyQ1VSN3FmWnVabUZ5am5WNzNPTFNQU2Q3RzQ=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[15]</b>习艳兵.急性脑梗塞患者血清MCP-1、VE-cadherin水平与神经功能、颈动脉粥样硬化的相关性[J].海南医学院学报, 2017, 23 (9) :1272-1275.
                            </a>
                        </p>
            </div>
        <!--reference end-->
        <!--footnote start-->
        <!--footnote end-->



    </div>

        <input id="fileid" type="hidden" value="XXGK201904015" />
        <input id="dpi" type="hidden" value="300" />
    </div>

<script>
var _hmt = _hmt || [];
(function() {
  var hm = document.createElement("script");
  hm.src = "https://hm.baidu.com/hm.js?6e967eb120601ea41b9d312166416aa6";
  var s = document.getElementsByTagName("script")[0];
  s.parentNode.insertBefore(hm, s);
})();
</script>

    


<input id="hid_uid" name="hid_uid" type="hidden" value="WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" />
<input id="hid_kLogin_headerUrl" name="hid_kLogin_headerUrl" type="hidden" value="/KLogin/Request/GetKHeader.ashx%3Fcallback%3D%3F" />
<input id="hid_kLogin_footerUrl" name="hid_kLogin_footerUrl" type="hidden" value="/KLogin/Request/GetKFooter.ashx%3Fcallback%3D%3F" />
<div class="btn-link" style="display: none"><a target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=XXGK201904015&amp;v=MTUyMjJDVVI3cWZadVptRnlqblY3M09QVFhNWmJHNEg5ak1xNDlFWVlRS0RIODR2UjRUNmo1NE8zenFxQnRHRnI=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">知网节</a></div>
<div class="popflow" id="popupTips" style="display: none;">
    <div class="popflowArr"></div>
    <div class="popflowCot">
        <div class="hd"><a href="javascript:void(0);" onclick="$('#popupTips').hide();$('#popupmsg').html('')" class="close">X</a></div>
        <div class="bd">
            <p class="mes" id="popupmsg" name="popupmsg"></p>
          
        </div>
    </div>
</div>
<input type="hidden" id="myexport" value="//kns.cnki.net" />

<input type="hidden" id="KPCAPIPATH" value="//ishufang.cnki.net" />
<input type="hidden" id="CitedTimes" value="" />
<div class="link" id="GLSearch" style="display: none;">
    <i class="icon-trangle"></i>
    <div class="inner">
        <a class="icon" id="copytext">复制</a>
        <a class="icon" target="_blank" onclick="searchCRFD(this)">工具书搜索</a>
    </div>
</div>




<input id="hidVirtualPath" name="hidVirtualPath" type="hidden" value="/kxreader" />
<script src="/kxreader/bundles/detail?v=842_VlRz_g1CMCLi-M0twVw-4EOFG_noWyi_OsMnrAg1"></script>

<script src="/kxreader/Scripts/layer.min.js" type="text/javascript"></script>

<div id="footerBox" class="rootw footer">
</div>
<script>
    if (typeof FlushLogin == 'function') {
        FlushLogin();
    }
    modifyEcpHeader(true);
</script>

<!--图片放大功能 start-->
<script src="/kxreader/bundles/imagebox?v=W4phPu9SNkGcuPeJclikuVE3PpRyIW_gnfjm_19nynI1"></script>

<script type="text/javascript">
    $(function () {
        var j = $.noConflict();
        j(function () {
            j(".zoom-in,.btn-zoomin").imgbox({
                'alignment': 'center',
                'allowMultiple': false,
                'overlayShow': true
            });
        })
    });
</script>
<!--图片放大功能 end-->
<div class="fixedbar">
    <div class="backtop hiddenV" id="backtop">
        <a id="backTopSide" href="javascript:scroll(0,0);" title=""></a>
    </div>
</div>
<script type="text/javascript" src="/kxreader/Scripts/MathJax-2.6-latest/MathJax.js?config=MML_HTMLorMML-full"></script>

</body>
</html>
